Skip to content

Study · Ex vivo tissue · rat · 2007

3 results

A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation.

Kidd M, Modlin IM, Black JW, Boyce M, Culler M

Regulatory peptides29 Apr 2007Cited by 25 (Europe PMC)

PMID17531331 (opens in a new tab)DOI10.1016/j.regpep.2007.04.002 (opens in a new tab)PepBankPUB-17531331
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In rat gastric cell preparations, lanreotide inhibited histamine secretion with an inhibitory concentration of 2.2 nM.

    In plain wordsIn lab tests with rat gastric cells, lanreotide inhibited histamine release at a reported inhibitory concentration of 2.2 nM.

    Peptide
    Lanreotide
    Outcome
    DecreaseHistamine secretion inhibition
    Study

    ratn: not reported in source

    Enriched gastric enterochromaffin-like cell preparations
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Inhibitory concentration
    2.2 nM
    histamine secretion

    Source sentences

    Summary
    Lanreotide inhibited secretion and proliferation (2.2 nM, 1.9 x 10(-10) M)
    2 context sentences
    Summary · context
    Since the ECL cell exhibits all three classes of receptor we evaluated and compared the effects of the gastrin receptor antagonist, (YF476), lanreotide (SST agonist) and novel dopaminergic agents (BIM53061 and BIM27A760) on ECL cell histamine secretion and proliferation.
    Summary · context
    Highly enriched (>98%) ECL cell preparations prepared from rat gastric mucosa using a FACS approach were studied.
  2. 02LabEx vivo tissueActivity measurement

    In rat gastric cell preparations, lanreotide inhibited proliferation with an inhibitory concentration of 1.9 x 10(-10) M.

    In plain wordsIn lab tests with rat gastric cells, lanreotide inhibited proliferation at a reported inhibitory concentration of 1.9 x 10(-10) M.

    Peptide
    Lanreotide
    Outcome
    DecreaseCell proliferation inhibition
    Study

    ratn: not reported in source

    Enriched gastric enterochromaffin-like cell preparations
    Outcome group
    Tumor growth · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Lanreotide inhibited secretion and proliferation (2.2 nM, 1.9 x 10(-10) M)
    2 context sentences
    Summary · context
    Since the ECL cell exhibits all three classes of receptor we evaluated and compared the effects of the gastrin receptor antagonist, (YF476), lanreotide (SST agonist) and novel dopaminergic agents (BIM53061 and BIM27A760) on ECL cell histamine secretion and proliferation.
    Summary · context
    Highly enriched (>98%) ECL cell preparations prepared from rat gastric mucosa using a FACS approach were studied.
  3. 03LabEx vivo tissueEfficacy outcome

    In rat gastric cell preparations, lanreotide increased YF476-mediated proliferation inhibition a further 5-fold.

    In plain wordsIn lab tests with rat gastric cells, adding lanreotide increased proliferation inhibition 5-fold compared with YF476 alone.

    Peptide
    Lanreotide
    Outcome
    DecreaseAdditional proliferation inhibition with YF476
    Study

    ratn: not reported in source

    Enriched gastric enterochromaffin-like cell preparations
    Comparator
    YF476 alone
    Outcome group
    Tumor growth · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Additional proliferation inhibition
    5 fold
    with YF476

    Source sentences

    Summary
    Lanreotide inhibited secretion and proliferation (2.2 nM, 1.9 x 10(-10) M) and increased YF476-inhibited proliferation a further 5-fold.
    2 context sentences
    Summary · context
    Since the ECL cell exhibits all three classes of receptor we evaluated and compared the effects of the gastrin receptor antagonist, (YF476), lanreotide (SST agonist) and novel dopaminergic agents (BIM53061 and BIM27A760) on ECL cell histamine secretion and proliferation.
    Summary · context
    Highly enriched (>98%) ECL cell preparations prepared from rat gastric mucosa using a FACS approach were studied.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.